Design and implementation of the canadian kidney disease cohort study (CKDCS): A prospective observational study of incident hemodialysis patients
© Bello et al; licensee BioMed Central Ltd. 2011
Received: 11 January 2011
Accepted: 16 February 2011
Published: 16 February 2011
Many nephrology observational studies use renal registries, which have well known limitations. The Canadian Kidney Disease Cohort Study (CKDCS) is a large prospective observational study of patients commencing hemodialysis in five Canadian centers. This study focuses on delineating potentially reversible determinants of adverse outcomes that occur in patients receiving dialysis for end-stage renal disease (ESRD).
The CKDCS collects information on risk factors and outcomes, and stores specimens (blood, dialysate, hair and fingernails) at baseline and in long-term follow-up. Such specimens will permit measurements of biochemical markers, proteomic and genetic parameters (proteins and DNA) not measured in routine care. To avoid selection bias, all consenting incident hemodialysis patients at participating centers are enrolled, the large sample size (target of 1500 patients), large number of exposures, and high event rates will permit the exploration of multiple potential research questions.
Data on the baseline characteristics from the first 1074 subjects showed that the average age of patients was 62 (range; 50-73) years. The leading cause of ESRD was diabetic nephropathy (41.9%), and the majority of the patients were white (80.0%). Only 18.7% of the subjects received dialysis in a satellite unit, and over 80% lived within a 50 km radius of the nearest nephrologist's practice.
The prospective design, detailed clinical information, and stored biological specimens provide a wealth of information with potential to greatly enhance our understanding of risk factors for adverse outcomes in dialysis patients. The scientific value of the stored patient tissue will grow as new genetic and biochemical markers are discovered in the future.
More than 1 million patients with end-stage renal disease (ESRD) receive renal replacement therapy (RRT) worldwide in the form of dialysis or transplantation, and this number is projected to reach 2.2 million by the year 2030 [1–3]. In Canada, about 21,000 individuals require hemodialysis (HD) treatment for ESRD, with an expected annual growth of 7% . Developed nations spend about 2-6% of their total healthcare budget for the provision of RRT to their ESRD population, which usually represents only about 0.02-0.6% of their total population [5, 6]. In addition, mortality for ESRD patients is 10 to 1000 times greater than in age matched controls with normal kidney function, and ESRD is also associated with very low quality of life [7–10]. The high costs of care for RRT, adverse outcomes and the increasing burden of ESRD make it a major global public health issue.
The widespread use of RRT to prolong life for people with ESRD has been one of the major advances in medicine . Nonetheless, the limitations of dialysis for treatment of ESRD remain problematic. As the number of patients treated grows, the costs, and morbidity and mortality remains high despite technical and scientific improvements [8, 11, 12]. Despite intensive investigation, our knowledge of factors that mediate uremic complications among people treated with dialysis remains inadequate[8, 13].
Observational studies are important sources of information to close knowledge gaps in every clinical discipline. However, most observational studies in ESRD have collected either good quality information on a small number of individuals, or poorer quality data on a much larger number of individuals. Many existing observational data are derived from renal registries such as the United States Renal Data Systems (USRDS) , European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) , and Australia and New Zealand Dialysis and Transplant (ANZDATA) ; or from prospective studies such as the Dialysis Outcomes and Practice Pattern Study (DOPPS) , the choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study , and European Uraemic Toxins (EUTox) Work Group database . Although these studies have made substantial contributions to our knowledge about uremia and its optimal treatment, they may have limitations including suboptimal statistical power, lack of detail in data collection, or inability to store a comprehensive battery of biological specimens for future analyses.
The Canadian Kidney Disease Cohort Study (CKDCS) is a large prospective observational study of patients commencing dialysis in five Canadian centers serving ethnically mixed populations (Vancouver, Calgary, Edmonton, Ottawa, and Toronto). This novel study focuses on identifying the potentially reversible determinants of the major complications associated with dialysis in an incident cohort of adult patients.
To assemble a prospective cohort of incident Canadian hemodialysis patients and associated database which contains research-quality information on patient characteristics, comorbid diseases and routine and novel laboratory markers and genetic data.
To utilize data from the cohort to test specific hypotheses about the independent relation between biochemical and genetic markers and cardiovascular disease (CVD) risk and outcomes such as mortality, hospitalization and quality of life measures
To rapidly capture information on the characteristics and health history of incident hemodialysis patients, using a structured patient interview and review of medical records.
To operate a specimen management and storage system so that diverse specimens (blood, dialysate, fingernails, hair) can be collected at dialysis initiation and eventually be assayed by new biochemical and genetic assays.
To make the data available to other academic investigators and collaborators if required.
In order to have the most representative registry, the CKDCS enrolls all incident adult (≥18 years of age) hemodialysis patients from the five participating renal programs. The sole exclusion criterion is failure to provide informed consent.
All subjects commencing chronic hemodialysis (HD) are approached by study staff within 8 weeks of commencing dialysis therapy. A variety of options for participating in the study are offered, depending on the interests of the patient (Appendix 1).
Medical Data Collection
Data Collection Synopsis
Background and demographic information
Age, sex, race, dialysis start date, education, employment status, postal code (to allow linkage to census data), provincial health card number (for linkage), hospital unit number, social support
Cause(s) of ESRD, tobacco use/dose, coronary disease, chronic heart failure, previous arrhythmia, cerebrovascular disease, peripheral vascular disease, diabetes mellitus, pulmonary disease, neurologic disease, psychiatric disease, musculoskeletal disease, gastrointestinal and hepatic diseases, cancer, eye disease, hepatitis, HIV, family history of premature CAD in first degree relatives
Nephrologist visit, interval between first nephrology visit and ESRD, vascular access, relevant labs (Hb, Ca, PO4, HCO3, albumin)
BP, HR, weight, height
Time, dialyzer, dialysate composition, blood flow, Bioimpedance measurements
Specific study questionnaire, Health Utilities Index
Routine laboratory data from dialysis monthly bloodwork
Frozen blood for biochemistry
Frozen plasma for special tests and proteomic studies (will not be thawed or refrozen)
Frozen blood for DNA/RNA
Excess/deficiency of trace elements
Source water collection from home and dialysis unit
Residual renal function
Timed urine collection for urea/creatinine
List of medications and dose
Vascular access history
Type and location of current access, number of prior temporary and permanent accesses
Vascular access events
Type, location at start and end of interval; all changes in access status; procedures, creation/placement
Dates, diagnosis, and procedures for each interval hospitalization
Dialysis status at end of reporting interval, date and cause of death
Determinants of Transplant referral
Patient and physician attitudes toward transplantation, intervals from transplant referral to transplant activation.
Quality of life
Kidney Disease Quality of Life Instrument (KDQOL)
Satisfaction with care
Specific study questionnaire
Coronary artery calcification/Cardiac geometry
Coronary CT scan/Cardiac MRI
Study Procedure Schedule
Study Visits Baseline
Year 2 and yearly
Medical record review
Coronary CT (separate consent form)
Sample collection (blood, dialysate/effluent, finger/toe nails, hair)
Home tap water collection
Genetic sample collection (separate consent form)
Control genetic sample collection (separate consent)
Attitudes toward Transplant
Whenever necessary, a translator is present during the consent and interview procedures. Quality of Life questionnaires (which must be completed by the study subject without assistance) are available in English, French, Chinese and Spanish and may be completed by hand or electronically.
Sample Collection and Processing
Blood, dialysate effluent, fingernail and hair samples are obtained at baseline, 6 months, 12 months and at each study visit thereafter, according to standard protocols. Blood samples are immediately divided into multiple aliquots, from which plasma, DNA, RNA and/or cells are extracted and separately stored. Dialysate specimens are aliquoted to allow future measurement of genetic and cellular material. Specimens are frozen at -80 degree Celcius. Specimens are sent to the Canadian Biosample Repository in Edmonton and are labeled using a unique study identifier to maintain confidentiality.
Source Water Collection
Source water used for dialysate is collected in triplicate four times annually from each dialysate unit (including satellite dialysis locations). Patients are also asked to bring a sample of their drinking water from home on two separate days during one week at baseline and month 6. Source water specimens are shipped to the study laboratory and frozen for future analysis.
Coronary CT and Cardiac MRI
A subset of 500 subjects will undergo imaging to determine the presence and extent of Coronary Artery Calcification (CAC) and Cardiac geometry including Left Ventricular Hypertrophy (LVH). CAC will be assessed by multi-slice computed tomography at two points during the study: baseline (within 3 months of dialysis initiation) and 12 months after dialysis initiation. All CT scans will be reported locally by an experienced reader for the presence, distribution and amount of CAC, using dedicated software (manufacturer dependent). Calcium mass, plaque volume and Agatston score will be calculated .
To ensure uniformity and high quality image acquisition, all sites must: (1) use ≥64-slice multidetector Computed Tomography Scan (MDCT) technology or better (2) led by level 3 accredited cardiologist/radiologist. Before the start of the study, each site will send ten anonymized CAC reports and data sets to the core lab for assessment of image quality/data transfer/reproducibility of results. For sites demonstrating excessive variation, the core lab will review the site protocol/analysis tools and work with the site to reach the standard needed.
Cardiac geometry (including LVH) will be assessed by cardiac magnetic resonance imaging (CMRI). Scanning is performed at baseline and at 12 months after dialysis initiation in these 500 participants. Left ventricular (LV) mass, and change in LV mass are analyzed as both quantitative traits and dichotomous end-points. All CMRI scans will be analyzed using dedicated software (manufacturer dependent) and reported locally by an experienced reader. Absolute and normalized to body surface area (BSA) left ventricular muscle mass, end diastolic blood pool volume, end systolic blood pool volume, ejection fraction, cardiac output and stroke volume will be calculated. Results forwarded to the core lab together with image data. To ensure uniformity and high quality image acquisition; all sites must: (1) use 1.5T CMR sequences (2) led by a level 3 CMRI certified radiologist/cardiologist. Before the start of the study, each site will send ten anonymized LV function data sets and results to the core lab for assessment of image quality/transfer capability and reproducibility of results. For sites demonstrating excessive variation, the core lab will review the site protocol/analysis tools and work with the site to reach the standard needed. An additional two studies will be requested to ensure the site fulfils all requirements.
All participating renal programs perform ongoing surveillance of bacteremia in HD patients as an infection control initiative. Renal programs routinely record the date and microbiological species associated with positive blood cultures, as well as patient-specific information such as health card number and demographic data. Data on the management of bacteremia are also collected including: whether antibiotics were prescribed, antibiotic type/duration, whether catheter removal/exchange occurred and whether the event was resolved. Recurrent bacteremia is defined as a repeat positive blood culture with the same species within 6 months of the index event, according to current guidelines . Periods of follow-up and any hospitalizations for infection or infectious complications within 2-8 weeks of the index culture are recorded.
Study subjects who die are identified by monthly follow-up by study coordinators; date of death is obtained from the renal programs. A prospectively defined method is used to ascertain the cause of death as previously published [20, 21]. A standardized form is completed by a study coordinator after obtaining the date of death. The forms are supplemented by information provided by the patient's physicians and next of kin where appropriate. This form, together with copies of the medical record, discharge summaries, autopsy/coroner's report (if available) are obtained and sent to two investigators for independent classification of the cause of death. On occasions when the cause of death differs between adjudicators, the site investigator acts as the tie breaker.
Additional Data Sources
Local Renal Program Databases
Contain detailed information on pre-dialysis, dialysis and kidney transplant patients. Data linkage will provide information on medication use, laboratory results, bacteremia incidence and management, and access blood flows.
Provincial Health Authorities Databases
The use of administrative data sources permit determination of disease incidence and prevalence using validated algorithms for common medical conditions such as hypertension , diabetes [23, 24], acute myocardial infarction , congestive heart failure  and stroke , as well as assessment of clinical, health outcomes and costing information . In addition to routine demographic information and dates of death, some administrative databases include information to permit the assessment of Aboriginal ethnicity, socio-economic status, and a six-digit postal code which enables unique geographic information system (GIS) analyses to be performed . Hospitalization information via diagnostic and procedure codes using ICD-9-CM and ICD-10) is available .
Census data includes the population counts of each geographic area, as well as information, for example, on whether it is in a rural location (Statistics Canada definition), average income, education levels, etc. The six-digit residential postal code for each subject is linked to these data using the Postal Code Conversion file.
Provincial Laboratory Services
Computerized provincial databases are used to obtain laboratory data recorded outside of the renal programs.
Study Data Management
Study data are stored in a Microsoft SQL database created specifically for this project. Wherever possible, free text fields, blank values and open-ended questions have been eliminated from the database. "Not available" and "not applicable" values are permitted. Data from enrolled subjects are either entered directly into the database using a Microsoft Access interface through dedicated, password controlled laptop computers or are first collected on paper forms. All paper forms identify subjects exclusively by initials and study numbers. Quality assurance reports are generated on a monthly basis for the purposes of ensuring standard and compliance with the study protocol. Working copies of the database used to perform analyses are stripped of uniquely identifying information such as provincial health care number.
The institutional review boards at the participating centers approved the study, and it is conducted according to the Helsinki declaration for medical research in humans.
The sample size and large number of exposures together with the high event rate will permit the exploration of multiple potential research questions. In addition, the availability of stored blood samples will allow the testing of hypotheses raised by data which becomes available in the future. The target sample size is 1500 subjects.
Potential Use of Study Data
This study will provide a combination of cross-sectional and prospective clinical data and biological specimens of huge potential for conduct of high quality observational studies and clinical trials (Figure 1).
Investigating the role of anemia, bone metabolism, inflammatory markers, endothelial dysfunction, genetic factors, and socio-demographic factors (age, gender, race, first nation status, residence location, socio-economic status) on CVD at dialysis inception
Assessment of pre-dialysis care and its impact on adverse outcomes
Access and utility of kidney transplantation
Determinants of all-cause mortality
Determinants of dialysis access failure and consequences
Determinants of poor quality of life and functional status
Assessment of care delivery quality, impact and satisfaction
Bacteremia screening: data on episodes and treatment
Potential for biomarker discovery and validation using array technology
Preliminary data on baseline patients' characteristics
Cohort patients, N(%)
62 (50, 73)
BMI, kg/m 2 *
26 (22, 31)
Cause of ESRD
Hypertensive/ischemic renal disease
Polycystic kidney disease
Congestive heart failure
Chronic lung disease
Peripheral vascular disease
Prior cardiac arrest
Satellite HD unit€
Type of access
Non tunnel CVC
34 (30, 37)
2.2 (2, 2.3)
Calcium X phosphate, mmol2/L2
3.6 (2.9, 4.5)
534 (424, 682)
252 (136, 472)
99 (89, 109)
1.6 (1.2, 1.9)
26.2 (10.7, 45.8)
24 (17, 31)
18.6 (14.6, 23.5)
1.4 (1.2, 1.7)
Distance to Nephrologist, km
51 - 100
101 - 200
The CKDCS uses a unique study design to assemble a cohort of subjects recruited at hemodialysis inception in Canada to prospectively collect detail clinical and laboratory data as well as novel biochemical and genetic markers. While clinical trials are considered best evidence to guide clinical care and policy, this study will inform important knowledge gaps for several reasons . First, observational studies are important sources of hypothesis-generating data about chronic diseases and their treatments . Second, collecting good quality observational data may reduce the risk of incorrect inferences [21, 31], based on retrospective studies or less detailed registry data [4, 5, 8, 13, 16]. Third, comprehensive high quality observational studies of dialysis patients remain an important research focus [21, 31].
An ideal cohort study in ESRD should consist of a well-characterized population of incident patients to avoid prevalence-incidence bias [29, 30, 32]. The CKDCS involves patients recruited at inception of dialysis with meticulous data collation, and monitoring for outcomes. The study will be large enough to allow adequate power to explore covariates simultaneously, and have sufficient variability in patient and treatment characteristics to allow exploration of the associations between these characteristics and various outcomes under investigation. The study will collect and quantify known covariates that might potentially affect relevant outcomes in dialysis patients (death, hospitalizations, access failure, quality of life, cost), and employ an accurate, unbiased method of ascertaining such outcomes.
The additional strength and novelty of this study is the collection and storage of materials (blood, dialysate, fingernails, hair, etc) so that new risk factors such as the impact of trace elements on outcomes can be measured and studied in the future as they arise. The storage of genomic DNA and plasma for future analyses is a strength given the emerging importance of genetic and proteomic analysis [33–35]. This has great potential for biomarker discovery and validation using array technology in future.
These unique characteristics make this study novel, topical and an extension of the existing observational databases on ESRD population. The largest such database is the USRDS, which although extremely useful, derives much of its information from billings data, which has significant limitations . For example, medical professionals do not generally enter data themselves, and the information collected is chiefly limited to the elements required for Medicare reimbursement. In general, quantified risk factors and information on laboratory results and medication use are not available. More recently, the DOPPS has sought to remedy some of these aforementioned limitations, but has been limited by lack of a biobanking platform and prospective imaging studies .
In conclusion, the CKDCS will capitalize on the unique demographic and multiethnic characteristics of the Canadian dialysis population, a supportive Canadian regulatory climate, and the established and productive collaborations between Canadian nephrology investigators to address the limitations of existing databases. It will also provide novel information on determinants of adverse outcomes in hemodialysis patients, because of its unique combination of detailed prospectively collected information and the availability of stored biological specimens. This will provide new platforms for clinical and translational observational studies and clinical trials among dialysis patients in the future.
Appendix 1: Study Consent Pathway
All subjects wishing to participate in the study are required to sign the Main CKDCS consent form which permits collection of health history and/or clinical laboratory data at baseline and during follow-up and will allow future analysis of stored blood specimens for non-genetic laboratory assays to examine "factors that influence the cause or treatment of heart or kidney disease".
1. Genetic Sample Consent - The Genetic Sample Consent form will permit proteomic and genetic testing (plasma and DNA) from stored peripheral blood and other available biological samples such as tissue, to examine the same research questions.
data and specimens may be obtained and used after the death of the subject
provincial and national databases can be accessed to provide obtain other information about their health
2. Control Genetic Sample consent - Whenever possible, control blood samples are collected from a family member or acquaintances of the study subject. These samples are used as controls for the genetic analyses. Eligible family members or acquaintances will include those who do not have kidney disease and are willing to provide samples with the understanding that they are used in an anonymous fashion as the control in genetic analyses. The same safeguards are taken to protect the privacy of these control subjects, as is taken for participants treated with dialysis.
3. CT consent - The Coronary CT consent permits a multi-slice coronary CT scan at baseline.
List of Abbreviations used
Australia and New Zealand Dialysis and Transplant
Body Surface Area
Coronary Artery Calcification
Choices for Healthy Outcomes in Caring for ESRD
Canadian Kidney Disease Cohort Study
Cardiac Magnetic Resonance Imaging
Complete blood count
Dialysis Outcomes and Practice Pattern Study
European Dialysis and Transplant Association
End-stage renal disease
European Uraemic Toxins
Geographic Information System
Health Utility Index questionnaire
Kidney Disease Quality of Life Questionnaire
Left Ventricular Hypertrophy
multidetector Computed Tomography Scan
Renal Replacement Therapy
United States Renal Data Systems.
Acknowledgements and Funding
The CKDCS is being funded by the Canadian Institutes of Health Research (CIHR), Abbott Laboratories, Alberta Heritage Foundation for Medical Research, and the Northern Alberta Renal Program.
- Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, et al: Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007, 72 (3): 247-259. 10.1038/sj.ki.5002343.View ArticlePubMedGoogle Scholar
- Meguid El Nahas A, Bello AK: Chronic kidney disease: the global challenge. Lancet. 2005, 365 (9456): 331-340.View ArticlePubMedGoogle Scholar
- Snyder JJ, Collins AJ: KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999-2004. Am J Nephrol. 2009, 30 (1): 44-54. 10.1159/000201014.View ArticlePubMedGoogle Scholar
- Anonymous: Treatment of End-Stage Organ Failure in Canada, 1999 to 2008. Canadian Organ Replacement Register (CORR). 2010, (Accessed 2nd November, 2010), [https://secure.cihi.ca/estore/productFamily.htm?pf=PFC1403&locale=en&lang=EN&mediatype=0]Google Scholar
- Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B, Liu J, Mau LW, McBean M, et al: United States Renal Data System 2008 Annual Data Report. Am J Kidney Dis. 2009, 53 (1 Suppl): S1-374.Google Scholar
- De Vecchi AF, Dratwa M, Wiedemann ME: Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant. 1999, 14 (Suppl 6): 31-41. 10.1093/ndt/14.suppl_6.31.View ArticlePubMedGoogle Scholar
- Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL, Akizawa T, Bommer J, Canaud BJ, Port FK, Held PJ: Health-related quality of life among dialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2003, 64 (5): 1903-1910. 10.1046/j.1523-1755.2003.00289.x.View ArticlePubMedGoogle Scholar
- Himmelfarb JIT: Haemodialysis. N Engl J Med. 2010, 363: 1833-1845. 10.1056/NEJMra0902710.View ArticlePubMedGoogle Scholar
- Manns B, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C: Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important determinants?. Clin Nephrol. 2003, 60 (5): 341-351.View ArticlePubMedGoogle Scholar
- McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA: The quality of life and cost utility of home nocturnal and conventional in-center hemodialysis. Kidney Int. 2003, 64 (3): 1004-1011. 10.1046/j.1523-1755.2003.00157.x.View ArticlePubMedGoogle Scholar
- Weinhandl ED, Foley RN, Gilbertson DT, Arneson TJ, Snyder JJ, Collins AJ: Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. J Am Soc Nephrol. 2010, 21 (3): 499-506. 10.1681/ASN.2009060635.View ArticlePubMedPubMed CentralGoogle Scholar
- Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F, Piera L, Bragg-Gresham JL, Feldman HI, Goodkin DA, et al: Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004, 19 (1): 108-120. 10.1093/ndt/gfg483.View ArticlePubMedGoogle Scholar
- Anonymous: European Uraemic Toxins (EUTox) Work Group. 2010, [http://uremic-toxins.org/imprint.html]Google Scholar
- Ronco P: Disease classification: a pitfall of the ERA/EDTA registry?. Nephrol Dial Transplant. 2010, 25 (4): 1022-1024. 10.1093/ndt/gfq022.View ArticlePubMedGoogle Scholar
- Australia and New Zealand Dialysis and Transplant Registry. 2009, (Accessed 16th November, 2010), [http://www.anzdata.org.au/v1/working_group_members.html]
- Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA: The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. Am J Kidney Dis. 2004, 44 (5 Suppl 2): 7-15. 10.1016/S0272-6386(04)01099-6.View ArticlePubMedGoogle Scholar
- Sozio SM, Armstrong PA, Coresh J, Jaar BG, Fink NE, Plantinga LC, Powe NR, Parekh RS: Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis: the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis. 2009, 54 (3): 468-477. 10.1053/j.ajkd.2009.01.261.View ArticlePubMedPubMed CentralGoogle Scholar
- van der Bijl N, Joemai RM, Geleijns J, Bax JJ, Schuijf JD, de Roos A, Kroft LJ: Assessment of Agatston coronary artery calcium score using contrast-enhanced CT coronary angiography. AJR Am J Roentgenol. 2010, 195 (6): 1299-1305. 10.2214/AJR.09.3734.View ArticlePubMedGoogle Scholar
- Mermel LA: Prevention of intravascular catheter infections--insights and prospects for hemodialysis catheters. Nephrologie. 2001, 22 (8): 449-451.PubMedGoogle Scholar
- Rocco MV, Yan G, Gassman J, Lewis JB, Ornt D, Weiss B, Levey AS: Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration. Am J Kidney Dis. 2002, 39 (1): 146-153. 10.1053/ajkd.2002.29905.View ArticlePubMedGoogle Scholar
- Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002, 347 (25): 2010-2019. 10.1056/NEJMoa021583.View ArticlePubMedGoogle Scholar
- Quan H, Khan N, Hemmelgarn BR, Tu K, Chen G, Campbell N, Hill MD, Ghali WA, McAlister FA: Validation of a case definition to define hypertension using administrative data. Hypertension. 2009, 54 (6): 1423-1428. 10.1161/HYPERTENSIONAHA.109.139279.View ArticlePubMedGoogle Scholar
- Hux JE, Ivis F, Flintoft V, Bica A: Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002, 25 (3): 512-516. 10.2337/diacare.25.3.512.View ArticlePubMedGoogle Scholar
- Austin PC, Daly PA, Tu JV: A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. Am Heart J. 2002, 144 (2): 290-296. 10.1067/mhj.2002.123839.View ArticlePubMedGoogle Scholar
- Lee DS, Donovan L, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV: Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care. 2005, 43 (2): 182-188. 10.1097/00005650-200502000-00012.View ArticlePubMedGoogle Scholar
- Kokotailo RA, Hill MD: Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10. Stroke. 2005, 36 (8): 1776-1781. 10.1161/01.STR.0000174293.17959.a1.View ArticlePubMedGoogle Scholar
- Hemmelgarn BR, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P, Pannu N, Ahmed SB, MacRae J, Scott-Douglas N, et al: Overview of the Alberta Kidney Disease Network. BMC Nephrol. 2009, 10: 30-10.1186/1471-2369-10-30.View ArticlePubMedPubMed CentralGoogle Scholar
- Heng D, Pong RW, Pitblado JR, Lagace C, Desmeules M: Sources of data for rural health research: development of an inventory of Canadian databases. J Agric Saf Health. 2005, 11 (2): 219-227.View ArticlePubMedGoogle Scholar
- Stel VS, Jager KJ, Zoccali C, Wanner C, Dekker FW: The randomized clinical trial: an unbeatable standard in clinical research?. Kidney Int. 2007, 72 (5): 539-542. 10.1038/sj.ki.5002354.View ArticlePubMedGoogle Scholar
- Jager KJ, Stel VS, Wanner C, Zoccali C, Dekker FW: The valuable contribution of observational studies to nephrology. Kidney Int. 2007, 72 (6): 671-675. 10.1038/sj.ki.5002397.View ArticlePubMedGoogle Scholar
- Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol. 2002, 13 (5): 1307-1320.PubMedGoogle Scholar
- Tripepi G, Jager KJ, Dekker FW, Wanner C, Zoccali C: Bias in clinical research. Kidney Int. 2008, 73 (2): 148-153. 10.1038/sj.ki.5002648.View ArticlePubMedGoogle Scholar
- Hong KW, Oh B: Overview of personalized medicine in the disease genomic era. BMB Rep. 2010, 43 (10): 643-648. 10.5483/BMBRep.2010.43.10.643.View ArticlePubMedGoogle Scholar
- Ding L, Wendl MC, Koboldt DC, Mardis ER: Analysis of next-generation genomic data in cancer: accomplishments and challenges. Hum Mol Genet. 2010, 19 (R2): R188-196. 10.1093/hmg/ddq391.View ArticlePubMedPubMed CentralGoogle Scholar
- Borovecki F, Habek M: Development of novel genomic blood biomarkers for neurodegenerative diseases. CNS Neurol Disord Drug Targets. 2010, 9 (6): 669-678.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/12/10/prepub